Neumann Diagnostics Automated Cervical Cancer Test
Neumann Diagnostics has launched its Confidence molecular test portfolio for cervical cancer screening. The test portfolio consists of a human papillomavirus test and an epigenetic biomarker and was evaluated in a multicentre clinical trial involving over 7,000 cervical samples collected from over 6,000 women. In HPV-positive women, aged 25 years or older, the test's sensitivity for severe cervical dysplasia or worse condition at baseline was about 92 percent and its specificity in the same group was about 74 percent. The clinical trial showed that Confidence tests found severe cases up to 12 months earlier than a Pap smear, according to the firm.